Cart summary

You have no items in your shopping cart.

KIM-161

SKU: orb3027974

Description

KIM-161 is a PIK3CA inhibitor. It demonstrates significant antiproliferative activity, with IC50 values of 1.428 and 1.562 µM against PI3KCA-mutant breast cancer cell lines MCF7 and T47D, respectively. KIM-161 induces apoptosis and cell cycle arrest by inhibiting the PI3K/AKT/mTOR signaling pathway, leading to ROS production. It is applicable for research on breast cancer and its PI3KCA-mutant subtypes.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Signal Transduction

Images & Validation

Key Properties

CAS Number2559686-28-9
MW439.51
FormulaC27H25N3O3
SMILESO=C\1N(C(C)=N/C1=C\C2=CC=C(OC)C=C2)C3=CC=C(CC(NCC4=CC=CC=C4)=O)C=C3
TargetPI3K,Reactive Oxygen Species,mTOR,Akt,Apoptosis

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

KIM-161 (orb3027974)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%